title: Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer.
authors.forename: Nancy
authors.initials: N
authors.lastname: Price
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
authors.forename: Thomas
authors.initials: T
authors.lastname: Hutson
authors.forename: Sara
authors.initials: S
authors.lastname: Mariani
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D018890:Chemoprevention; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D018120:Finasteride / Q000008:administration & dosage; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage; D017312:Toremifene / Q000008:administration & dosage
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004791:Enzyme Inhibitors; D020845:Selective Estrogen Receptor Modulators; D018120:Finasteride; D017312:Toremifene; D042944:Cholestenone 5 alpha-Reductase